| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Cash provided by financing activities | 11,896,585 | 4,863,760 |
| Effect of exchange rate changes | 376,272 | 369,605 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -1,574,088 | -3,687,144 |
| Cash and cash equivalents at beginning of period | 10,417,558 | - |
| Cash and cash equivalents at end of period | 8,843,470 | - |
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)